Blockbuster immunology drugs facing patent expiry and biosimilar competition - Pharmaceutical Technology
Patent expiry dates for biologicals: 2016 update - GaBI Journal
Global Generic Drugs Market Report 2022: Rapid Patent Expiry of Branded Drugs Creates Opportunities
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Patent expiry dates for biologicals: 2018 update - GaBI Journal
Coreg: Glaxo Wins $235 Million Verdict Against Teva Over Patent Infringement - Bloomberg
One, two, three, gone: Teva loses third patent on new Copaxone formula | Fierce Pharma
The biggest drug patent losses for 2013 - GaBI Journal
Patent expiry dates for biologicals: 2017 update - GaBI Journal
Several blockbuster patents to expire in 2023 - BioStock
Patent expiry dates for biologicals: 2016 update - GaBI Journal
List - 91 Drug Patents that are Expiring between 2020 to 2022 - GreyB
Teva Pharma Plunges After Two U.S. Copaxone Patents Invalidated | Investor's Business Daily
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha
Drug Patent Expirations and the “Patent Cliff”
US drug expiries: 2020 to be a big year for drug market exclusivity expiries
Does Drug Patent Evergreening Prevent Generic Entry? – DrugPatentWatch - Make Better Decisions
Truvada patent expires, potentially opening 'new doors' for PrEP access
Top pharma companies by sales loss due to patent expirations until 2018 | Statista
Top 5 expired blockbuster drugs - Clinical Trials Arena
Can new CEO Erez Vigodman inject life back into Teva? | World Finance
Teva abused patent system and spread misinformation about a Copaxone rival, European officials say
